Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Telix Pharmaceuticals Limited (TLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TLX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20.19
1 Year Target Price $20.19
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.41% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.23B USD | Price to earnings Ratio 173.44 | 1Y Target Price 20.19 |
Price to earnings Ratio 173.44 | 1Y Target Price 20.19 | ||
Volume (30-day avg) 2 | Beta 2.38 | 52 Weeks Range 10.70 - 30.36 | Updated Date 07/31/2025 |
52 Weeks Range 10.70 - 30.36 | Updated Date 07/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-20 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 7.62% | Operating Margin (TTM) 9.49% |
Management Effectiveness
Return on Assets (TTM) 7.97% | Return on Equity (TTM) 20.49% |
Valuation
Trailing PE 173.44 | Forward PE 77.52 | Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 |
Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 | ||
Enterprise Value to Revenue 12.96 | Enterprise Value to EBITDA 113.13 | Shares Outstanding 334724000 | Shares Floating 282348658 |
Shares Outstanding 334724000 | Shares Floating 282348658 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Telix Pharmaceuticals Limited
Company Overview
History and Background
Telix Pharmaceuticals Limited is a global biopharmaceutical company focused on developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) technology. Founded in 2005, Telix has grown from a research-driven enterprise to a commercial-stage company with operations across multiple continents.
Core Business Areas
- Therapeutics: Development and commercialization of targeted radiopharmaceuticals for the treatment of various cancers.
- Diagnostics: Development and commercialization of imaging agents for the detection and staging of cancers and other diseases.
Leadership and Structure
Telix Pharmaceuticals is led by a team of experienced executives in the biopharmaceutical industry. The organizational structure consists of functional departments including R&D, Manufacturing, Commercial Operations, and Regulatory Affairs.
Top Products and Market Share
Key Offerings
- Illuccix (Kit for the preparation of gallium (68Ga) gozetotide injection): A diagnostic radiopharmaceutical imaging agent used for prostate cancer. Illuccix holds significant market share in PSMA PET imaging. Competitors include Lantheus (PYLARIFY). US Revenue ~$336M (2023)
- TLX591 (ProstACT):: A therapeutic product in clinical development for metastatic castrate-resistant prostate cancer (mCRPC). Competitors include Novartis (Pluvicto).
Market Dynamics
Industry Overview
The radiopharmaceutical market is experiencing growth driven by advancements in molecular imaging and targeted therapies for cancer and other diseases.
Positioning
Telix is positioned as a leader in the development and commercialization of radiopharmaceuticals, particularly in prostate cancer. Their competitive advantage lies in their proprietary technology and expanding product portfolio.
Total Addressable Market (TAM)
The TAM for radiopharmaceuticals is estimated to be several billions of dollars annually and expanding. Telix's strong pipeline and commercialized products position them to capture a significant portion of this market, especially in prostate cancer imaging and therapy.
Upturn SWOT Analysis
Strengths
- Strong product portfolio focused on unmet medical needs
- Proprietary technology platform
- Experienced management team
- Commercialized product (Illuccix) generating revenue
Weaknesses
- Reliance on regulatory approvals for product launches
- High R&D expenses
- Competition from established pharmaceutical companies
- Limited manufacturing capacity
Opportunities
- Expanding indications for existing products
- Strategic partnerships and acquisitions
- Growth in the radiopharmaceutical market
- Advancements in molecular imaging and targeted therapies
Threats
- Regulatory changes
- Competition from new entrants
- Patent expiration
- Economic downturns
Competitors and Market Share
Key Competitors
- LNTH
- NVS
Competitive Landscape
Telix competes with established pharmaceutical companies in the radiopharmaceutical market. Their focus on prostate cancer and proprietary technology provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Telix has demonstrated substantial revenue growth since the approval of Illuccix.
Future Projections: Analysts project continued revenue growth driven by increased adoption of Illuccix and potential approvals of pipeline products.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity and advancing clinical trials for pipeline products.
Summary
Telix Pharmaceuticals is a company with strong revenue growth from their prostate cancer diagnostic product and a growing pipeline. The company still faces high R&D expenses and competition from larger companies, but it is poised to capitalize on the growing radiopharmaceutical market. Expanding indications for current drugs and manufacturing capabilities remain critical. Financial stability requires vigilance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Telix Pharmaceuticals Limited
Exchange NASDAQ | Headquaters North Melbourne, VIC, Australia | ||
IPO Launch date 2024-11-14 | Co-Founder, MD, Group CEO & Executive Director Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telixpharma.com |
Full time employees - | Website https://telixpharma.com | ||
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.